Nymox Advances in the Treatment of Deadly E. coli Food Contamination; Nymox NXC-4720 E. coli Product In Late Stage Development.

Business Editors/Health/Medical Writers

MAYWOOD, N.J.--(BUSINESS WIRE)--Oct. 9, 2003

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it is taking more than one approach to the serious public health problem posed by the contamination of meat and other food and drink products by potentially deadly E.coli O157:H7 bacteria.

The first approach uses the Company's NXC-4720 product to address the problem of E. coli O157:H7 contamination at the stage of meat production. The Company recently announced that NXC-4720 has reached significant milestones in product development and has been validated in further independent tests. The Company is involved in ongoing further validation studies.

A second approach as set out in its recently signed letter of intent with scientists at Health Canada looks to develop products for an earlier stage in the food production chain. These products aim to reduce E. coli O157 infection in cattle. Run-off from cattle operations have been implicated in the contamination of public drinking water in recent years, among other problems.

"E. coli O157:H7 contamination of food and drink products and of water supplies is widely recognized as a serious problem both for public health and for the food industry," said Dr. Michael Munzar, Medical Director of Nymox. "Studies of Nymox's NXC-4720 product thus far have shown excellent results. NXC-4720 shows real promise for this serious health care concern for both consumers and industry."

E. coli O157:H7 bacterial contamination is a major public health problem throughout the world. The Centers for Disease Control and Prevention estimates that in the United States alone, 73,000 human cases occur every year as a result of E. coli O157 contamination of food and drink products and of water supplies. This type of E. coli infection can cause severe bloody diarrhea and abdominal cramps and can lead to kidney failure, particularly in young children and in the elderly, with often serious long term and sometimes fatal results.

One United States Department of Agriculture (USDA) study estimated the direct and indirect costs of foodborne E. coli O157 infections at over $650 million per year. In 2002 alone, over 23 million pounds of meat were recalled in the U.S. because of possible E. coli contamination, affecting all sectors of the meat industry from large meat processors to local supermarkets and many consumers. On average, Americans consume over 65 pounds of beef per person per year.

The Food Safety and Inspection Service (FSIS) of the USDA has targeted E. coli O157 contamination in meat with more stringent testing and tighter regulations. In a recently released report, Enhancing Public Health: Strategies for the Future, the FSIS outlined new initiatives to encourage the use by food processors of new technologies such as antimicrobial agents, in their products.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.